BioLight, 2 Asian Firms Invest $7.2M in Glaucoma Treatment Tech Company IOPtima
BioLight Life Sciences Investments Ltd. and two Asia-based venture capital firms will provide $7.2 million in funding to BioLight subsidiary IOPtima Ltd.
Financing will support commercialization and regulatory approval of the IOPtimate system — a minimally invasive surgical ophthalmic device — in the U.S. The CO
2 laser-based technology enables the performance of a filtration surgery to treat glaucoma without penetrating the inner part of the eyeball. The procedure provides high efficacy, and allows for reductions in postoperative complications and use of eye drops, according to BioLight.
The system has been sold in Hong Kong, Poland, Hungary, Romania and Peru; distribution agreements are under negotiation in additional countries.
The two venture firms and BioLight will invest $6 million and $1.2 million, respectively, on the basis of a $13.5 million premoney valuation of IOPtima. BioLight will hold approximately 71 percent of IOPtima's issued and outstanding shares. The private placement is expected to close within the next few weeks, subject to standard closing terms.
For more information, visit
www.bio-light.co.il.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024